Skip to Main Content

The Food and Drug Administration on Friday expanded the approval of Vascepa, a fish-oil-derived medicine, to allow the drug’s maker to say it prevents heart attacks, strokes, and related health problems in people who are at high cardiovascular risk.

The approval reverses decades of mixed results for fish-oil-based drugs and could result in Vascepa being prescribed to millions of patients, potentially resulting in a windfall for the drug’s maker, Amarin Pharmaceuticals, which sells no other products.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
    • Ha, ha, my thoughts exactly! I notice the article uses relative risk and doesn’t mention whether this treatment actually extends life, but we do get an important clue:

      “all the outcomes were lumped together for statistical power.”

      A giant red flag but the FDA is color blind so it’s all good…

    • @JOEL unlike you, clearly being an Amarin stock holder making up claims, I am just a scientist looking at it for what it is.
      BTW, if what you say was demonstrably true, Vascepa would have been approved years ago, with much smaller and shorter trials.
      Instead, not only they didn’t use the right placebo, that is unrefined fish oil, to prove that their highly refined version has therapeutic effect as compared to over the counter products. They actually chronically poisoned the control group by administering them mineral oil, a substance rich in carcinogenic PAH. A substance under investigation by EFSA.

Comments are closed.